BioStock: CombiGene welcomes AmbioPharm as CDMO in pain project

19 September 2023 - 09:04

CombiGene has entered into a partnership with AmbioPharm, a US-based contract manufacturer for the COZY01 peptide-based pain project, jointly undertaken with Zyneyro. With extensive experience in peptide development and manufacturing, AmbioPharm meets all regulatory criteria, setting the stage for toxicology studies and human studies. AmbioPharm's ability for commercial production also positions them as a potential long-term partner in the COZY01 venture.

Read the article at

This is a press release from BioStock - Connecting Innovation & Capital.

Provided by: Cision
Nasdaq First North GM Stockholm (Sweden)
CombiGene AB
CombiGene is a gene therapy explorer based in Sweden. The Company is engaged in developing new methods for the treatment of neurological diseases and for epileptic patients who cannot be helped by available medical treatments at present....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More